Many skin diseases,such as atopic dermatitis(AD),are featured with the dysbiosis of skin microbiota.The clinically recommended options for AD treatments suffer from poor outcomes and high side-effects,leading to sever...Many skin diseases,such as atopic dermatitis(AD),are featured with the dysbiosis of skin microbiota.The clinically recommended options for AD treatments suffer from poor outcomes and high side-effects,leading to severe quality-of-life impairment.To deal with this long-term challenge,we develop a living bacterial formu-lation(Hy@Rm)that integrates skin symbiotic bacteria of Roseomonas mucosa with poly(vinyl pyrrolidone),poly(vinyl alcohol)and sodium alginate into a skin dressing by virtue of the Ca^(2+)-mediated cross-linking and the freezing-thawing(F-T)cycle method.Hy@Rm dressing creates a favorable condition to not only serve as extrinsic culture harbors but also as nutrient suppliers to support R.mucosa survival in the harsh microenvi-ronment of AD sites to defeat S.aureus,which predominantly colonizes AD skins as an indigenous pathogen,mainly through the secretion of sphingolipids metabolites by R.mucosa like a therapeutics bio-factory.Mean-while,this elaborately designed skin dressing could accelerate wound healing,normalize aberrant skin char-acters,recover skin barrier functions,alleviate AD-associated immune/inflammation responses,functioning like a combinational therapy.This study offers a promising means for the topical bacteria transplant to realize effective microbe biotherapy toward the skin diseases feature with microbe milieu disorders,including but not limited to AD disease.展开更多
Atrial fibrillation(AF)is a growing global health burden,with a prevalence of over 52.55 million cases.Rising disability-adjusted life-years,increasing age,and disparities in care have contributed to the worsening sev...Atrial fibrillation(AF)is a growing global health burden,with a prevalence of over 52.55 million cases.Rising disability-adjusted life-years,increasing age,and disparities in care have contributed to the worsening severity and mortality of AF.Modifiable risk factors,such as hypertension,obesity,and diabetes mellitus,are associated with alterations in gut microbiota,making the gut-heart axis a potential therapeutic target.Gut dysbiosis influences AF pathogenesis through inflam-mation,metabolic disruption,and autonomic dysfunction.Key mechanisms include gut barrier dysfunction,short-chain fatty acid(SCFA)depletion,lipopoly-saccharides(LPS)-induced inflammation,and ferroptosis-mediated atrial remodeling.Trimethylamine N-oxide,bile acids,and tryptophan metabolites contribute to arrhythmogenic remodeling.Emerging evidence suggests that dietary interventions,including prebiotics and probiotics,as well as gut surveillance,may help mitigate AF progression.Clinical implications of gut modulation in AF include person-alized dietary strategies,microbiome assessment through metagenomic sequencing,and targeted interventions such as SCFA-based therapies and ferroptosis inhibition.Metabolite surveillance,including LPS and indoxyl sulfate monitoring,may influence the effectiveness of anticoagulant and antiarrhythmic therapy.Despite growing mechanistic evidence linking gut dysbiosis to AF,clinical applications remain unexplored.This review summarizes the current understanding of the gut microbiome's role in AF.展开更多
The gut microbiome plays a pivotal role in immune homeostasis and systemic inflammatory regulation,both of which are critically involved in the pathogenesis and progression of pediatric leukemias.Recent evidence revea...The gut microbiome plays a pivotal role in immune homeostasis and systemic inflammatory regulation,both of which are critically involved in the pathogenesis and progression of pediatric leukemias.Recent evidence reveals that children with leukemia often exhibit distinct gut microbiome profiles at diagnosis,marked by reduced microbial diversity and the enrichment of pro-inflammatory taxa such as Enterococcus and Streptococcus.This microbial dysbiosis may promote leukemogenesis by disrupting immune regulation and driving chronic inflammation.Chemotherapy significantly alters the gut microbiome,inducing dysbiosis characterized by a loss of beneficial commensals and the dominance of pathobionts.Specific microbial signatures,such as the enrichment of Bacteroides,correlate with reduced inflammation and improved prognosis,underscoring the gut microbiome's prognostic value.Emerging therapies,including dietary adjustments,probiotics,and fecal gut microbiome transplantation,aim to restore microbial balance and reduce treatment-related complications.Moreover,gut microbiome profiling shows potential for identifying biomarkers linked to leukemia predisposition,paving the way for early diagnosis and tailored preventive strategies.This mini-review explores recent advancements in understanding the influence of the gut microbiome on pediatric leukemias,emphasizing its role as both a therapeutic target and a prognostic biomarker.Integrating gut microbiome research into clinical practice may help optimize treatment outcomes and improve quality of life for children with leukemia.展开更多
Metabolic dysfunction-associated fatty liver disease(MAFLD)now affects roughly one-quarter of the world’s population,reflecting the global spread of obesity and insulin resistance.Reframing non-alcoholic fatty liver ...Metabolic dysfunction-associated fatty liver disease(MAFLD)now affects roughly one-quarter of the world’s population,reflecting the global spread of obesity and insulin resistance.Reframing non-alcoholic fatty liver disease as MAFLD emphasizes its metabolic roots and spotlights the gut-liver axis,where intestinal dysbiosis acts as a key driver of hepatic injury.Altered microbial com-munities disrupt epithelial integrity,promote bacterial translocation,and trigger endotoxin-mediated inflammation that accelerates steatosis,lipotoxicity,and fibrogenesis.Concurrent shifts in bile acid signaling and short-chain fatty acid profiles further impair glucose and lipid homeostasis,amplifying cardiometabolic risk.Epidemiological studies reveal pervasive dysbiosis in MAFLD cohorts,linked to diet quality,sedentary behavior,adiposity,and host genetics.Newly developed microbiome-derived biomarkers,advanced elastography,and integrated multi-omics panels hold promise for non-invasive diagnosis and stratification,although external validation remains limited.In early trials,interventions that re-engineer the microbiota including tailored pre-/pro-/synbiotics,rational diet patterns,next-generation fecal microbiota transplantation,and bile-acid-modulating drugs show encouraging histological and metabolic gains.Optimal care will likely couple these tools with weight-centered lifestyle programmes in a pre-cision-medicine framework.Key challenges include inter-ethnic variability in microbiome signatures,the absence of consensus treatment algorithms,and regulatory barriers to live biotherapeutics.Rigorous longitudinal studies are required to translate mechanistic insight into durable clinical benefit and improve patient-centered outcome measures.展开更多
Many recent studies have shown that the gut microbiome plays important roles in human physiology and pathology.Also,microbiome-based therapies have been used to improve health status and treat diseases.In addition,agi...Many recent studies have shown that the gut microbiome plays important roles in human physiology and pathology.Also,microbiome-based therapies have been used to improve health status and treat diseases.In addition,aging and neurodegenerative diseases,including Alzheimer’s disease and Parkinson’s disease,have become topics of intense interest in biomedical research.Several researchers have explored the links between these topics to study the potential pathogenic or therapeutic effects of intestinal microbiota in disease.But the exact relationship between neurodegenerative diseases and gut microbiota remains unclear.As technology advances,new techniques for studying the microbiome will be developed and refined,and the relationship between diseases and gut microbiota will be revealed.This article summarizes the known interactions between the gut microbiome and neurodegenerative diseases,highlighting assay techniques for the gut microbiome,and we also discuss the potential therapeutic role of microbiome-based therapies in diseases.展开更多
The gut microbiome has emerged as a critical player in cancer pathogenesis and treatment response.Dysbiosis,an imbalance in the gut microbial community,impacts tumor initiation,progression,and therapy outcomes.Specifi...The gut microbiome has emerged as a critical player in cancer pathogenesis and treatment response.Dysbiosis,an imbalance in the gut microbial community,impacts tumor initiation,progression,and therapy outcomes.Specific bacterial species have been associated with either promoting or inhibiting tumor growth,offering potential targets for therapeutic intervention.The gut microbiome in-fluences the efficacy and toxicity of conventional treatments and cutting-edge immunotherapies,highlighting its potential as a therapeutic target in cancer care.However,translating microbiome research into clinical practice requires addres-sing challenges such as standardizing methodologies,validating microbial bio-markers,and ensuring ethical considerations.Here,we provide a comprehensive overview of the gut microbiome's role in cancer highlighting the need for on-going research,collaboration,and innovation to harness its full potential for im-proving patient outcomes in oncology.The current editorial aims to explore these insights and emphasizes the need for standardized methodologies,validation of microbial biomarkers,and interdisciplinary collaboration to translate microbiome research into clinical applications.Furthermore,it underscores ethical consider-ations and regulatory challenges surrounding the use of microbiome-based the-rapies.Together,this article advocates for ongoing research,collaboration,and innovation to realize the full potential of microbiome-guided oncology in impro-ving patient care and outcomes.展开更多
Acute pancreatitis(AP)is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden.Gut microbiota disturbance,mucosal barrier failure,and bacterial translocation are ide...Acute pancreatitis(AP)is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden.Gut microbiota disturbance,mucosal barrier failure,and bacterial translocation are identified as the dominant cause of infected pancreatic necrosis and high mortality.With the advance of high-throughput sequencing,imbalance between beneficial and facultative pathogenic microorganisms with their metabolic activities in the development of AP has been increasingly recognized,whereas it remains unclear whether dysbacteriosis is the dominant cause of aggravating AP,or merely reflecting different epidemiological or environmental factors at the individual level.This review discussed the alterations of the gut microbiota and their metabolites during AP with detailed molecular mechanisms.Importantly,it highlights microbiome-based medical therapies which influence gut barrier function and immune homeostasis to mitigate inflammatory responses in AP.Our review will provide a novel roadmap of gastrointestinal microecology in AP progression,and contribute to the future development of microbiome-based diagnostic and therapeutic strategies in clinical practice.展开更多
基金National Natural Science Foundation of China(52131302,51973164,22135005 and 51833007)Fundamental Research Funds for the Central Universities(2042021kf0037)+1 种基金All of the animal experiments were conducted under protocols(AUP,WP20210510)Institutional Animal Care and Use Committee(IACUC)of the Animal Experiment Center of Wuhan University(Wuhan,China).
文摘Many skin diseases,such as atopic dermatitis(AD),are featured with the dysbiosis of skin microbiota.The clinically recommended options for AD treatments suffer from poor outcomes and high side-effects,leading to severe quality-of-life impairment.To deal with this long-term challenge,we develop a living bacterial formu-lation(Hy@Rm)that integrates skin symbiotic bacteria of Roseomonas mucosa with poly(vinyl pyrrolidone),poly(vinyl alcohol)and sodium alginate into a skin dressing by virtue of the Ca^(2+)-mediated cross-linking and the freezing-thawing(F-T)cycle method.Hy@Rm dressing creates a favorable condition to not only serve as extrinsic culture harbors but also as nutrient suppliers to support R.mucosa survival in the harsh microenvi-ronment of AD sites to defeat S.aureus,which predominantly colonizes AD skins as an indigenous pathogen,mainly through the secretion of sphingolipids metabolites by R.mucosa like a therapeutics bio-factory.Mean-while,this elaborately designed skin dressing could accelerate wound healing,normalize aberrant skin char-acters,recover skin barrier functions,alleviate AD-associated immune/inflammation responses,functioning like a combinational therapy.This study offers a promising means for the topical bacteria transplant to realize effective microbe biotherapy toward the skin diseases feature with microbe milieu disorders,including but not limited to AD disease.
文摘Atrial fibrillation(AF)is a growing global health burden,with a prevalence of over 52.55 million cases.Rising disability-adjusted life-years,increasing age,and disparities in care have contributed to the worsening severity and mortality of AF.Modifiable risk factors,such as hypertension,obesity,and diabetes mellitus,are associated with alterations in gut microbiota,making the gut-heart axis a potential therapeutic target.Gut dysbiosis influences AF pathogenesis through inflam-mation,metabolic disruption,and autonomic dysfunction.Key mechanisms include gut barrier dysfunction,short-chain fatty acid(SCFA)depletion,lipopoly-saccharides(LPS)-induced inflammation,and ferroptosis-mediated atrial remodeling.Trimethylamine N-oxide,bile acids,and tryptophan metabolites contribute to arrhythmogenic remodeling.Emerging evidence suggests that dietary interventions,including prebiotics and probiotics,as well as gut surveillance,may help mitigate AF progression.Clinical implications of gut modulation in AF include person-alized dietary strategies,microbiome assessment through metagenomic sequencing,and targeted interventions such as SCFA-based therapies and ferroptosis inhibition.Metabolite surveillance,including LPS and indoxyl sulfate monitoring,may influence the effectiveness of anticoagulant and antiarrhythmic therapy.Despite growing mechanistic evidence linking gut dysbiosis to AF,clinical applications remain unexplored.This review summarizes the current understanding of the gut microbiome's role in AF.
文摘The gut microbiome plays a pivotal role in immune homeostasis and systemic inflammatory regulation,both of which are critically involved in the pathogenesis and progression of pediatric leukemias.Recent evidence reveals that children with leukemia often exhibit distinct gut microbiome profiles at diagnosis,marked by reduced microbial diversity and the enrichment of pro-inflammatory taxa such as Enterococcus and Streptococcus.This microbial dysbiosis may promote leukemogenesis by disrupting immune regulation and driving chronic inflammation.Chemotherapy significantly alters the gut microbiome,inducing dysbiosis characterized by a loss of beneficial commensals and the dominance of pathobionts.Specific microbial signatures,such as the enrichment of Bacteroides,correlate with reduced inflammation and improved prognosis,underscoring the gut microbiome's prognostic value.Emerging therapies,including dietary adjustments,probiotics,and fecal gut microbiome transplantation,aim to restore microbial balance and reduce treatment-related complications.Moreover,gut microbiome profiling shows potential for identifying biomarkers linked to leukemia predisposition,paving the way for early diagnosis and tailored preventive strategies.This mini-review explores recent advancements in understanding the influence of the gut microbiome on pediatric leukemias,emphasizing its role as both a therapeutic target and a prognostic biomarker.Integrating gut microbiome research into clinical practice may help optimize treatment outcomes and improve quality of life for children with leukemia.
文摘Metabolic dysfunction-associated fatty liver disease(MAFLD)now affects roughly one-quarter of the world’s population,reflecting the global spread of obesity and insulin resistance.Reframing non-alcoholic fatty liver disease as MAFLD emphasizes its metabolic roots and spotlights the gut-liver axis,where intestinal dysbiosis acts as a key driver of hepatic injury.Altered microbial com-munities disrupt epithelial integrity,promote bacterial translocation,and trigger endotoxin-mediated inflammation that accelerates steatosis,lipotoxicity,and fibrogenesis.Concurrent shifts in bile acid signaling and short-chain fatty acid profiles further impair glucose and lipid homeostasis,amplifying cardiometabolic risk.Epidemiological studies reveal pervasive dysbiosis in MAFLD cohorts,linked to diet quality,sedentary behavior,adiposity,and host genetics.Newly developed microbiome-derived biomarkers,advanced elastography,and integrated multi-omics panels hold promise for non-invasive diagnosis and stratification,although external validation remains limited.In early trials,interventions that re-engineer the microbiota including tailored pre-/pro-/synbiotics,rational diet patterns,next-generation fecal microbiota transplantation,and bile-acid-modulating drugs show encouraging histological and metabolic gains.Optimal care will likely couple these tools with weight-centered lifestyle programmes in a pre-cision-medicine framework.Key challenges include inter-ethnic variability in microbiome signatures,the absence of consensus treatment algorithms,and regulatory barriers to live biotherapeutics.Rigorous longitudinal studies are required to translate mechanistic insight into durable clinical benefit and improve patient-centered outcome measures.
基金by a National Key Science and Technology Project of China(2018YFC2000500,03)the National Natural Science Foundation of China(81790631 and 81703430)the CAMS Innovation Fund for Medical Sciences(2019-I2M-5-045)。
文摘Many recent studies have shown that the gut microbiome plays important roles in human physiology and pathology.Also,microbiome-based therapies have been used to improve health status and treat diseases.In addition,aging and neurodegenerative diseases,including Alzheimer’s disease and Parkinson’s disease,have become topics of intense interest in biomedical research.Several researchers have explored the links between these topics to study the potential pathogenic or therapeutic effects of intestinal microbiota in disease.But the exact relationship between neurodegenerative diseases and gut microbiota remains unclear.As technology advances,new techniques for studying the microbiome will be developed and refined,and the relationship between diseases and gut microbiota will be revealed.This article summarizes the known interactions between the gut microbiome and neurodegenerative diseases,highlighting assay techniques for the gut microbiome,and we also discuss the potential therapeutic role of microbiome-based therapies in diseases.
文摘The gut microbiome has emerged as a critical player in cancer pathogenesis and treatment response.Dysbiosis,an imbalance in the gut microbial community,impacts tumor initiation,progression,and therapy outcomes.Specific bacterial species have been associated with either promoting or inhibiting tumor growth,offering potential targets for therapeutic intervention.The gut microbiome in-fluences the efficacy and toxicity of conventional treatments and cutting-edge immunotherapies,highlighting its potential as a therapeutic target in cancer care.However,translating microbiome research into clinical practice requires addres-sing challenges such as standardizing methodologies,validating microbial bio-markers,and ensuring ethical considerations.Here,we provide a comprehensive overview of the gut microbiome's role in cancer highlighting the need for on-going research,collaboration,and innovation to harness its full potential for im-proving patient outcomes in oncology.The current editorial aims to explore these insights and emphasizes the need for standardized methodologies,validation of microbial biomarkers,and interdisciplinary collaboration to translate microbiome research into clinical applications.Furthermore,it underscores ethical consider-ations and regulatory challenges surrounding the use of microbiome-based the-rapies.Together,this article advocates for ongoing research,collaboration,and innovation to realize the full potential of microbiome-guided oncology in impro-ving patient care and outcomes.
基金supported by the National Natural Science Foundation of China(82270665,82070658,81871974)the Natural Science Foundation of Heilongjiang Province(TD2021H001)the Open Fund of Key Laboratory of Hepatoaplenic Surgery,Ministry of Education,Harbin,China(GPKF202201).
文摘Acute pancreatitis(AP)is one of the most common acute abdomen diseases with increasing incidence and substantial healthcare burden.Gut microbiota disturbance,mucosal barrier failure,and bacterial translocation are identified as the dominant cause of infected pancreatic necrosis and high mortality.With the advance of high-throughput sequencing,imbalance between beneficial and facultative pathogenic microorganisms with their metabolic activities in the development of AP has been increasingly recognized,whereas it remains unclear whether dysbacteriosis is the dominant cause of aggravating AP,or merely reflecting different epidemiological or environmental factors at the individual level.This review discussed the alterations of the gut microbiota and their metabolites during AP with detailed molecular mechanisms.Importantly,it highlights microbiome-based medical therapies which influence gut barrier function and immune homeostasis to mitigate inflammatory responses in AP.Our review will provide a novel roadmap of gastrointestinal microecology in AP progression,and contribute to the future development of microbiome-based diagnostic and therapeutic strategies in clinical practice.
